SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CNSI Cambridge Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brett Koplin who wrote (3)7/13/1996 1:18:00 PM
From: John B. Anderson   of 675
 
Brett/All: I also have a long position in CNSI and expect big things from it everytime I am reassured by the analyst. The potential market is huge. I get a little nervous, however, about similar drugs that other companies had in development whose trials were discontinued because of "contra-indications (side-effects)."

BTW, this same analyst told me (in a kind of off the cuff remark) that if this drug does successfully go through the Phase III trials now ongoing (with the able sponsorship and guidance of the huge German pharmaceutical firm Boeringer) this could be an $80 stock. That's a pretty good risk/reward ratio at today's price, don't you think?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News